title: A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group.
abstract: OBJECTIVE
  To evaluate the efficacy of an anti-CD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA).
  
  
  METHODS
  A total of 104 evaluable patients were enrolled in a multicenter, double-blind, multiple-dose, placebo-controlled study of CD5-IC.
  
  
  RESULTS
  Treatment with CD5-IC in doses up to 8 mg/m2/day for 4 days in 1 month failed to produce marked or prolonged T cell depletion and was no more effective than placebo in ameliorating disease manifestations. An unexpectedly high placebo response was observed in 48% of the patients. Adverse events were correlated with the dose of CD5-IC, but the treatment was generally well-tolerated.
  
  
  CONCLUSIONS
  At the doses used in this study, CD5-IC was ineffective for treating RA.
authors.affiliation: Vanderbilt University, Nashville, Tennessee 37232, USA.
authors.forename: N J
authors.initials: NJ
authors.lastname: Olsen
authors.forename: R H
authors.initials: RH
authors.lastname: Brooks
authors.forename: J J
authors.initials: JJ
authors.lastname: Cush
authors.forename: P E
authors.initials: PE
authors.lastname: Lipsky
authors.forename: E W
authors.initials: EW
authors.lastname: St Clair
authors.forename: E L
authors.initials: EL
authors.lastname: Matteson
authors.forename: K N
authors.initials: KN
authors.lastname: Gold
authors.forename: G W
authors.initials: GW
authors.lastname: Cannon
authors.forename: C G
authors.initials: CG
authors.lastname: Jackson
authors.forename: W J
authors.initials: WJ
authors.lastname: McCune
authors.forename: D A
authors.initials: DA
authors.lastname: Fox
authors.forename: B
authors.initials: B
authors.lastname: Nelson
authors.forename: T
authors.initials: T
authors.lastname: Lorenz
authors.forename: V
authors.initials: V
authors.lastname: Strand
mesh_terms: D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000276:immunology / Q000628:therapy*; D018956:CD5 Antigens / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008212:Lymphocyte Depletion; D008875:Middle Aged; D012276:Ricin; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018956:CD5 Antigens; D018796:Immunoconjugates; D012276:Ricin